Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IMRN

Immuron Limited ADR

Dec 13 • 04:00PM ET

2.13

Dollar change -0.07
Percentage change -3.39	%

Healthcare • Biotechnology • Australia • NASD

Peers: DVAX ALT OCGN BCRX AQST GERN TFFP MCRB AVIR MNOV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.80	Insider Own	-	Shs Outstand	5.70M	Perf Week	6.26%
Market Cap	12.18M	Forward P/E	-	EPS next Y	-0.01	Insider Trans	-	Shs Float	3.25M	Perf Month	7.34%
Income	-4.55M	PEG	-	EPS next Q	-0.01	Inst Own	0.19%	Short Float	0.21%	Perf Quarter	-20.99%
Sales	3.21M	P/S	3.79	EPS this Y	-33.34%	Inst Trans	-50.48%	Short Ratio	0.84	Perf Half Y	-5.12%
Book/sh	1.49	P/B	1.43	EPS next Y	50.00%	ROA	-36.40%	Short Interest	0.01M	Perf Year	0.25%
Cash/sh	1.36	P/C	1.56	EPS next 5Y	-	ROE	-42.27%	52W Range	1.59 - 5.96	Perf YTD	13.35%
Dividend Est.	-	P/FCF	-	EPS past 5Y	2.81%	ROI	-53.09%	52W High	-64.34%	Beta	-
Dividend TTM	-	Quick Ratio	4.87	Sales past 5Y	119.81%	Gross Margin	68.06%	52W Low	33.67%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	5.46	EPS Y/Y TTM	-78.77%	Oper. Margin	-175.97%	RSI (14)	57.85	Volatility	9.52% 7.92%
Employees	-	Debt/Eq	0.01	Sales Y/Y TTM	164.30%	Profit Margin	-141.71%	Recom	1.00	Target Price	5.00
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-161.79%	Payout	-	Rel Volume	0.06	Prev Close	2.20
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	103.24%	Earnings	Aug 30	Avg Volume	8.13K	Price	2.13
SMA20	8.34%	SMA50	6.55%	SMA200	-10.48%	Trades		Volume	511	Change	-3.39%

Dec-06-24 09:17AM	UPDATE: Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
08:35AM	Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th (GlobeNewswire)
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESSWIRE)
08:35AM	Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th (GlobeNewswire)
Dec-02-24 06:00AM	Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th (GlobeNewswire)
06:33PM	Loading…
Nov-21-24 06:33PM	Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event (GlobeNewswire)
Nov-18-24 08:30AM	Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event (ACCESSWIRE)
Oct-30-24 07:00AM	Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now (GlobeNewswire)
Oct-29-24 07:00AM	Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now (GlobeNewswire)
Oct-16-24 06:00AM	Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference (GlobeNewswire) +7.49%
Oct-15-24 06:00AM	Immuron Travelan continued strong sales growth (GlobeNewswire) -15.76%
Oct-04-24 06:30AM	NMRC Reports Results for Campylobacter Controlled Human Infection Model Study (GlobeNewswire)
Sep-25-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 2 on September 26 (GlobeNewswire)
Sep-24-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now (GlobeNewswire) +11.92%
Sep-05-24 11:54AM	Immuron Plans Phase 2 Trial for IMM-529 following FDA review (GlobeNewswire)
07:00AM	Loading…
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
Aug-20-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire) +8.06%
Aug-16-24 06:00AM	Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan (GlobeNewswire)
Aug-15-24 06:14PM	Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference (GlobeNewswire)
Aug-07-24 06:00AM	Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect (GlobeNewswire)
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-15-24 08:00AM	Immuron announces record Travelan sales globally, Australia and USA (GlobeNewswire) +6.36%
Jul-02-24 06:00AM	Immuron requests pre-IND meeting for IMM-529 with FDA filing (GlobeNewswire)
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-05-24 06:00AM	Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference (GlobeNewswire)
May-31-24 06:00AM	Immuron CEO Steven Lydeamore to present at Peak Sky High (GlobeNewswire)
06:00AM	Immuron Board Changes (GlobeNewswire)
May-08-24 07:50AM	Presenting on the Emerging Growth Conference 70 Day 2 on May 9 Register Now (GlobeNewswire)
May-07-24 07:00AM	Presenting on the Emerging Growth Conference 70 Day 1 on May 8 Register Now (GlobeNewswire)
06:00AM	Loading…
06:00AM	Immuron Limited to Present at the Emerging Growth Conference (GlobeNewswire)
May-03-24 06:00AM	Immuron Director Resignation (GlobeNewswire)
Apr-15-24 06:00AM	Immuron to host Live Virtual Event (GlobeNewswire)
Apr-10-24 06:00AM	Immuron Travelan sales continued strong growth (GlobeNewswire) +8.53%
Mar-07-24 06:00AM	Immuron Announces Positive Results Support Travelan progress to Phase 3 Clinical Trials in the US (GlobeNewswire) +175.74%
Feb-21-24 06:00AM	Immuron Presentation Australian Biologics Festival 2024 (GlobeNewswire)
Feb-13-24 06:00AM	Immuron achieves record Travelan sales (GlobeNewswire)
Feb-08-24 06:00AM	Immuron CEO, Steven Lydeamore Investor Webinar Presentation (GlobeNewswire)
Jan-16-24 06:00AM	Immuron achieves record half yearly Travelan sales (GlobeNewswire)
Dec-22-23 06:00AM	Immuron Clinical Trials Update (GlobeNewswire)
Dec-04-23 06:00AM	Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study (GlobeNewswire)
Nov-28-23 06:33AM	Immuron CEO, Steven Lydeamore Investor Webinar Presentation (GlobeNewswire) +5.70%
Nov-13-23 06:00PM	Immuron CEO Steven Lydeamore Investor Webinar Presentation (GlobeNewswire) +6.25% +11.18%
Oct-30-23 07:21AM	Immuron CEO Steven Lydeamore presented at AusBioInvest (GlobeNewswire)
Oct-18-23 06:00AM	Immuron Announces Travelan Clinical Study Cohort 2 commences (GlobeNewswire)
Oct-11-23 06:00AM	Immuron achieves record quarterly Travelan sales (GlobeNewswire)
Sep-18-23 07:30AM	Immuron Limited Announces Participation in the LD Micro Main Event XVI (Newsfile)
Sep-14-23 01:30PM	Immuron hails record monthly sales of Travelan (News Direct)
Sep-13-23 06:00AM	Immuron achieves record monthly Travelan® sales (GlobeNewswire)
Sep-11-23 06:00AM	Immuron CEO, Steven Lydeamore to present at H.C. Wainwright (GlobeNewswire)
Aug-23-23 08:30AM	Planet MicroCap Review Magazine for Summer 2023 Now Online (ACCESSWIRE)
Aug-14-23 06:00AM	Immuron to present at the Military Health System Research Symposium (GlobeNewswire)
Jul-26-23 02:45PM	Immuron welcomes launch of Travelan on Amazon US (News Direct)
Jul-25-23 06:00AM	Immuron Announces First Patients Enrolled in Travelan® Clinical Study (GlobeNewswire)
Jul-24-23 06:00AM	Immuron CEO, Steven Lydeamore to present at Bioshares (GlobeNewswire)
Jul-19-23 08:30AM	Immuron Ltd. Describes How their Gastrointestinal and Digestive Health Immune Supplements Work + FY23 Sales Announcement in New CEO Video Interview on Planet MicroCap (ACCESSWIRE)
Jul-11-23 06:00AM	Immuron Business Update - Ateria Health launches Juvia in Australia (GlobeNewswire)
Jul-05-23 06:00AM	Immuron FY23 Sales increase 136% on FY22 Sales (GlobeNewswire) +7.44%
Jun-30-23 06:00AM	Immuron Chairman Transition (GlobeNewswire) +6.31%
Jun-22-23 06:00AM	Immuron Business Update: Letter to Shareholders (GlobeNewswire)
May-30-23 06:00AM	Immuron Initiates Recruitment of Travelan® Clinical Study (GlobeNewswire)
May-16-23 07:30AM	Immuron Limited Announces Participation in the LD Micro Invitational XIII (Newsfile) +5.80%
May-08-23 01:11PM	FDA Lifts Clinical Hold From Immuron's New Campylobacter ETEC Therapeutic Study (Benzinga) +43.32%
06:00AM	Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation (GlobeNewswire)
May-02-23 06:00AM	Immuron CEO, Steven Lydeamore to present at Coffee Microcaps (GlobeNewswire) -9.76%
Apr-19-23 06:00AM	Immuron Q3 FY23 Business Update Presentation (GlobeNewswire) -10.65%
Apr-11-23 06:00AM	Q3 FY23 Business Update Webinar Notification (GlobeNewswire)
Apr-06-23 06:00AM	Immuron Q3 Sales reach 150% of 1H Sales (GlobeNewswire)
Feb-15-23 06:00AM	Immuron CEO, Steven Lydeamore to host an investor webinar (GlobeNewswire)
Jan-25-23 06:00AM	Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic (GlobeNewswire)
Jan-18-23 05:00AM	US Department of Defense Uniformed Services University Clinical Evaluation of Travelan Achieves 150 Recruitment Milestone (GlobeNewswire)
Jan-17-23 07:10AM	Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease (GlobeNewswire)
Dec-23-22 06:00AM	Immuron Receives FDA Approval for Travelan IND Application (GlobeNewswire) +18.63%
Dec-05-22 06:00AM	Immuron Submits IND Application To FDA for Travelan (GlobeNewswire) +6.93%
Nov-16-22 07:00AM	Immuron completes strategic investment in leading gut health biotech Ateria Health (GlobeNewswire)
Oct-26-22 06:00AM	Immuron CEO, Steven Lydeamore to present at AusBioInvest (GlobeNewswire)
Oct-13-22 10:28AM	Immuron Announces Strategic Investment In UK-Based Gut Health Company (Benzinga) +5.24%
06:00AM	Immuron strategic investment in leading gut health biotech Ateria Health (GlobeNewswire)
Oct-04-22 06:00AM	Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron (GlobeNewswire) +12.34%
Aug-29-22 07:00AM	Immuron CEO, Steven Lydeamore, to host an investor webinar (GlobeNewswire)
Aug-19-22 07:23AM	Immuron Pulls Plug On COVID-19 Treatment Hopeful, Citing Changing Landscape (Benzinga)
06:00AM	Immuron Update on IMM-124E SARS-CoV-2 Research (GlobeNewswire)
Jul-26-22 07:07AM	Immuron's IND Application For Bacterial Infection Candidate Placed On Clinical Hold (Benzinga) -5.18%
06:00AM	Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic (GlobeNewswire)
Jul-11-22 06:00AM	Immuron North American Travelan® Sales up 494% and Global sales up 431% (GlobeNewswire)
Jul-07-22 06:00AM	Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease (GlobeNewswire) +16.75%
May-11-22 06:00AM	Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic (GlobeNewswire)
May-09-22 06:00AM	US Department of Defense Uniformed Services University Clinical Evaluation of Travelan (GlobeNewswire)
May-05-22 08:22PM	Immuron appoints Mr. Steven Lydeamore as Chief Executive Officer (GlobeNewswire)
Apr-27-22 06:00AM	Immuron Travelan® Global sales up 216% (GlobeNewswire) +5.19%
Apr-19-22 07:33AM	Immuron new MTEC project proposal Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease (GlobeNewswire)
Mar-25-22 05:21AM	We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate (Simply Wall St.)
Mar-16-22 09:30AM	Appointment of Paul Brennan as Non-Executive Director (GlobeNewswire)
Jan-17-22 06:00AM	Immuron Receives AUD $306,154 R&D Tax Concession Refund (GlobeNewswire)
Jan-13-22 06:00AM	Immuron Receives European Patent on Drug Composition to Treat Travelers Diarrhea (GlobeNewswire) -8.09%
Jan-12-22 02:58PM	IMRN Stock Alert: What Is the Huge Catalyst Sending Immuron Soaring? (InvestorPlace) +46.18%
07:28AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
06:34AM	Immuron stock rockets after funding by U.S. DoD of new research agreement (MarketWatch)
06:00AM	Immuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for Travelan (GlobeNewswire)
04:59AM	Immuron Surges On U.S. DoD Funding For Travelan Research (Investing.com)

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce on mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994, and is headquartered in Carlton, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMRN

Immuron Limited ADR

Upgrade your FINVIZ experience